Imfinzi 50 mg/ml
As listed in the register: Imfinzi 50 mg/ml, concentraat voor oplossing voor infusie
50 mg/ml · concentraat voor oplossing voor infusie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Durvalumab
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (IMFINZI). It describes the substance, not this exact product.
Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment.
PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-31
Safety of the active substance
From the US prescribing label for the same active substance (IMFINZI). It describes the substance, not this exact product.
Most common adverse reactions (≥ 20%) of patients with resectable, Stage II/III NSCLC [neoadjuvant /adjuvant]) are anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Durvalumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 50 mg/ml |
| Form | concentraat voor oplossing voor infusie |
| Classification | L01FF03 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Imfinzi 50 mg/ml, concentraat voor oplossing voor infusie |
| RVG | EU/1/18/1322 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).